Given that Ccl17-gene deficient mice fed either a control diet or a HFD are protected from developing DMM-induced OA pain-like behaviour and exhibit less severe arthritis [11], we reasoned it to be important to determine whether an anti-CCL17 mAb could ameliorate therapeutically DMM-induced OA pain-like behaviour and disease in a dose-dependent manner under both dietary conditions. The gene discussed is CCL17; the disease is arthritic joint disease.